Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous nano CD5-CAR T cells
- Development stage
- Phase 2
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Autologous nano CD5-CAR T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory T-cell malignancies, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The therapy utilizes a patient's own T cells, which are genetically modified to express a CAR targeting the CD5 antigen, a glycoprotein found on the surface of most mature T cells and T-cell leukemias. A key innovation in this therapy is the use of a nanobody-based (VHH) binding domain instead of a conventional single-chain variable fragment (scFv), which may enhance the stability and specificity of the CAR. Developed by the Institute of Hematology & Blood Diseases Hospital in China, the therapy is currently undergoing Phase 1/2 clinical evaluation to assess its safety, optimal dosing, and efficacy in patients with advanced T-cell cancers.
- Other names
- nano CD5-CAR T cellsCD5-targeted CAR-T cellsCD-5-targeted CAR-T cellsCD 5-targeted CAR-T cellsautologous CD5-targeted CAR-T cells
02
Targets
CD5 (T-cell surface glycoprotein CD5)
Beyond the preview
Go deeper on autologous nano CD5-CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous nano CD5-CAR T cells.